Pharming GroupPHAR +0.84%77 PS Ratio is 2.80 as of Jul. 03, 2026, which is 29% below its 10-year median of 3.97. GuruFocus rates PHAR with a GF Score™ of 77/100 and a GF Value™ of $14.36 (Fairly Valued). The stock has 1 warning sign investors should review. Among 933 Biotechnology companies, Pharming Group ranks better than 77.81% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Pharming Group's share price is $13.77.
Pharming Group's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was $4.91. Hence, Pharming Group's PS Ratio for today is 2.80.
The historical rank and industry rank for Pharming Group's PS Ratio or its related term are showing as below:
PHAR'
s PS Ratio Range Over the Past 10 Years
Min: 1.58 Med: 3.97 Max: 9.85
Current: 2.89
During the past 13 years, Pharming Group's highest PS Ratio was 9.85. The lowest was 1.58. And the median was 3.97.
PHAR's PS Ratio is ranked better than 77.81% of 933
companies
in the Biotechnology industry
Industry Median: 9.64
vs PHAR: 2.89
Pharming Group revenue per share is in decline over the past 12 months.
During the past 12 months, the average Revenue per Share Growth Rate of Pharming Group was -3.20% per year.
During the past 3 years, the average Revenue per Share Growth Rate was 16.20% per year.
During the past 5 years, the average Revenue per Share Growth Rate was 11.60% per year.
During the past 10 years, the average Revenue per Share Growth Rate was 25.50% per year.
During the past 13 years, Pharming Group's highest 3-Year average Revenue per Share Growth Rate was 97.50% per year. The lowest was -42.90% per year. And the median was 12.40% per year.
Back to Basics: PS Ratio
Pharming Group (NAS:PHAR) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Pharming Group PS Ratio Related Terms
Pharming Group PS Ratio Historical Data
* Premium members only.
The historical data trend for Pharming Group's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Pharming Group's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pharming Group PS Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Pharming Group's PS Ratio distribution charts can be found below:
* The bar in red indicates where Pharming Group's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Pharming Group's Share Price of today is $13.77. Pharming Group's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $4.91.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Pharming Group (PHAR) has a PS Ratio of 2.80 as of Jul. 03, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Pharming Group and its competitors. This is 29% below median its historical median of 3.97. Over the past decade, Pharming Group's PS Ratio has ranged from 1.58 to 9.85. According to the industry distribution chart, Pharming Group ranks #207 out of 933 companies in the Biotechnology industry, placing it in the top 22.2%.
Is Pharming Group's PS Ratio too high?
Pharming Group's current PS Ratio of 2.80 is 29% below median its 10-year median of 3.97. Over the past 10 years, this metric has ranged from a low of 1.58 to a high of 9.85. The Biotechnology industry median PS Ratio is 9.64. Pharming Group's value of 2.80 is 71% below this industry median. Based on the distribution chart, Pharming Group ranks #207 out of 933 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Pharming Group has a GF Score™ of 77/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Pharming Group's PS Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Pharming Group ranks #207 out of 933 companies for PS Ratio. This places Pharming Group in the top 22% of its industry — outperforming the majority of peers. The industry median PS Ratio is 9.64. Pharming Group's value of 2.80 is 71% below this benchmark. Historically, Pharming Group's own PS Ratio has ranged from 1.58 to 9.85 over the past decade. While the company's 10-year median is 3.97 vs. the industry median of 9.64, Pharming Group has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Biotechnology company?
The median PS Ratio among Biotechnology companies is 9.64, based on 933 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Pharming Group's current PS Ratio of 2.80 is 71% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Pharming Group and its competitors. For the Biotechnology industry, the median PS Ratio is 9.64 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Pharming Group's current PS Ratio is 2.80, which is 29% below median its own 10-year median of 3.97. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pharming Group stock overvalued right now?
Based on GuruFocus' analysis, Pharming Group (PHAR) is currently considered Fairly Valued. The stock's GF Value™ is $14.36, compared to a current price of $13.77 — trading 4.1% below its estimated fair value. The current PS Ratio is 2.80, which is 29% below median its 10-year median of 3.97 and 71% below the Biotechnology industry median of 9.64. Pharming Group's overall GF Score™ is 77/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Pharming Group (PHAR), the current PS Ratio is 2.80 as of Jul. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Pharming Group (PHAR) Overvalued in 2026?
Based on GuruFocus' analysis, Pharming Group stock appears to be undervalued.
The current stock price of $13.77 is trading 4.1% below its estimated GF Value™ of $14.36.
GuruFocus considers Pharming Group to be Fairly Valued.
Key valuation signals for PHAR:
PS Ratio: 2.80 (29% below median its 10-year median of 3.97)
GF Value™: $14.36 vs. price of $13.77 (4.1% below fair value)
Industry Position: 71% below the Biotechnology median (#207 of 933)
No single metric tells the full story. See the PHAR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Pharming Group is a biotechnology company focused on developing and commercializing therapies for rare and ultra-rare diseases, particularly immunological and genetic conditions with high unmet need. It operates as an integrated company with capabilities across clinical development, manufacturing, regulatory affairs, and commercialization, supported by scientific and operational expertise. It leverages its efficient infrastructure to expand its pipeline and improve patient access to treatment. The Company operates in the United States, Europe, and the rest of the world, with the United States contributing the majority of its revenue.
77GF Score
Get the complete analysis for PHAR
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PHAR has been successfully added to your 
